Add to ORKGRecent advances in pharmacological immune modulation against tumor cells has dramatically changed the paradigm of cancer treatment. Checkpoint inhibitor therapy is a form of cancer immunotherapy already in clinical setting but also under active basic and clinical investigation. Nevertheless, some patients are primary unresponsive or develop ulterior resistance to these family of drugs. This review aims to update the basic molecular mechanism of resistance as well as the current strategies for checkpoint inhibitor selection in order to propose new approaches to individualize the use of these novel therapies
The genetic and epigenetic aberrations that underlie immune resistance lead to tumors that are refra...
The release of negative regulators of immune activation (immune checkpoints) that limit antitumor re...
Cancer immunotherapy utilizing blockade of the PD-1/PD-L1 checkpoint has revolutionized the treatmen...
Immunotherapies seek to unleash the immune system against cancer cells. While a variety of immunothe...
Cancer is one of the main public health problems in the world. Systemic therapies such as chemothera...
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer over the last decade...
Abstract The advent of immunotherapy, especially checkpoint inhibitor-based immunotherapy, has provi...
Cancer immunotherapy has fundamentally altered cancer treatment; however, its efficacy is limited to...
Cancer is one of the main public health problems in the world. Systemic therapies such as chemothera...
The development and clinical application of immune modulation represent one of the most extraordinar...
The development and clinical application of immune modulation represent one of the most extraordinar...
In the 1990s, the application of immunotherapy approaches to target cancer cells resulted in signifi...
A proportion of patients with lung cancer experience long-term clinical benefit with immune checkpoi...
Prolonged survival and durable responses in several late-stage cancers such as melanoma and lung can...
Checkpoint inhibitors act by blocking physiologic mechanisms coopted by tumor cells to evade immune ...
The genetic and epigenetic aberrations that underlie immune resistance lead to tumors that are refra...
The release of negative regulators of immune activation (immune checkpoints) that limit antitumor re...
Cancer immunotherapy utilizing blockade of the PD-1/PD-L1 checkpoint has revolutionized the treatmen...
Immunotherapies seek to unleash the immune system against cancer cells. While a variety of immunothe...
Cancer is one of the main public health problems in the world. Systemic therapies such as chemothera...
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer over the last decade...
Abstract The advent of immunotherapy, especially checkpoint inhibitor-based immunotherapy, has provi...
Cancer immunotherapy has fundamentally altered cancer treatment; however, its efficacy is limited to...
Cancer is one of the main public health problems in the world. Systemic therapies such as chemothera...
The development and clinical application of immune modulation represent one of the most extraordinar...
The development and clinical application of immune modulation represent one of the most extraordinar...
In the 1990s, the application of immunotherapy approaches to target cancer cells resulted in signifi...
A proportion of patients with lung cancer experience long-term clinical benefit with immune checkpoi...
Prolonged survival and durable responses in several late-stage cancers such as melanoma and lung can...
Checkpoint inhibitors act by blocking physiologic mechanisms coopted by tumor cells to evade immune ...
The genetic and epigenetic aberrations that underlie immune resistance lead to tumors that are refra...
The release of negative regulators of immune activation (immune checkpoints) that limit antitumor re...
Cancer immunotherapy utilizing blockade of the PD-1/PD-L1 checkpoint has revolutionized the treatmen...